← Leaderboards
Arnold S. Freedman
Dana-Farber Cancer Institute
$1,699,815
Attributed
$1,699,815
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,699,815 · 4
By mechanism
R21$1,136,642 · 2
R01$337,039 · 1
P01$226,134 · 1
Top collaborators
No co-investigators on record.
Most similar at Dana-Farber Cancer Institute
Same institution · by research overlap
- John G. Gribben$4,031,248
- Donna S. Neuberg$10,202,432
- A Thomas Look$30,189,128
- Scott A Armstrong$21,470,003
- Margaret A Shipp$7,796,368
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchNonhodgkin'S LymphomaNeoplasm /Cancer ImmunotherapyHuman SubjectTissue /Cell CultureFlow CytometryHuman Therapy EvaluationNeoplasm /Cancer Relapse /RecurrenceB LymphocyteDendritic CellsPatient Oriented ResearchCell MigrationBone MarrowCell ProliferationCell Growth RegulationApoptosisEnzyme Linked Immunosorbent AssayExtracellular MatrixCombination Cancer TherapyCell DifferentiationClinical TrialsComputed Axial TomographyClinical Trial Phase IiCell Cycle
Grant awards (8)
CpG Plus Rituximab Therapy in Follicular Lymphoma$282,732
R21 · FY2005 · CA
CpG Plus Rituximab Therapy in Follicular Lymphoma$284,550
R21 · FY2004 · CA
Etanercept Therapy in Follicular Lymphoma$284,611
R21 · FY2003 · CA
Etanercept Therapy in Follicular Lymphoma$284,749
R21 · FY2002 · CA
INTEGRIN SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIA$170,491
R01 · FY2001 · CA
TRANSLATIONAL THERAPEUTIC STRATEGIES FOR LOW GRADE LYMPHOMA$0
P01 · FY2001 · CA
TRANSLATIONAL THERAPEUTIC STRATEGIES FOR LOW GRADE LYMPHOMA$226,134
P01 · FY2000 · CA
INTEGRIN SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIA$166,548
R01 · FY2000 · CA